Wird geladen...
Docetaxel-Related Toxicity in Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer
BACKGROUND: Docetaxel plus androgen deprivation therapy (ADT) offers a survival benefit in metastatic hormone-sensitive prostate cancer (mHSPC). However, one trial evaluating docetaxel in mHSPC (GETUG-AFU15) showed unexpected toxicity; raising concerns that docetaxel may carry increased toxicity whe...
Gespeichert in:
| Veröffentlicht in: | Med Oncol |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5298886/ https://ncbi.nlm.nih.gov/pubmed/27300548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-016-0793-1 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|